Orsini tapped as exclusive partner on AVLAYAH
By HME News Staff
Updated 12:21 PM CDT, Wed April 22, 2026
ELK GROVE VILLAGE, Ill. – Orsini, a provider of rare disease pharmacy solutions, is the exclusive specialty pharmacy partner for Denali Therapeutics' AVLAYAH, an FDA-approved enzyme replacement therapy for the treatment of neurologic manifestations of Hunter syndrome (mucopolysaccharidosis type II, or MPS II) when initiated in presymptomatic or symptomatic pediatric patients weighing at least 5 kg prior to advanced neurologic impairment. As part of this program, Orsini will provide comprehensive home infusion support to ensure patients can access therapy in the comfort and convenience of their own homes, as recommended and supervised by a healthcare provider. MPS II is a genetic metabolic condition in which the body does not produce enough of the enzymes required to break down sugars into simpler molecules. AVLAYAH is a brain-penetrant enzyme replacement therapy designed to assist in breaking down these sugar molecules and prevent further buildup. It is the twentieth enzyme replacement therapy, and the fifth treatment for MPS, to join Orsini's Neurology Center of Excellence. "Orsini has been serving MPS patients for over 16 years, and we're proud to add AVLAYAH to our portfolio," said Darin DeCarlo, Orsini's chief commercial officer. "We're thrilled that this partnership with Denali allows us to extend our ability to serve this rare disease community and continue to offer it best-in-class patient care."
Comments